Novel agents for the treatment of type 2 diabetes

Ralph A Defronzo, Curtis L Triplitt, Muhammad A Abdul-ghani, Eugenio Cersosimo

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Impaired insulin secretion, increased hepatic glucose production, and decreased peripheral glucose utilization are the core defects responsible for the development and progression of type 2 diabetes. However, the pathophysiology of this disease also includes adipocyte insulin resistance (increased lipolysis), reduced incretin secretion/sensitivity, increased glucagon secretion, enhanced renal glucose reabsorption, and brain insulin resistance/neurotransmitter dysfunction. Although current diabetes management focuses on lowering blood glucose, the goal of therapy should be to delay disease progression and eventual treatment failure. Recent innovative treatment approaches target the multiple pathophysiological defects present in type 2 diabetes. Optimal management should include early initiation of combination therapy using multiple drugs with different mechanisms of action. This review examines novel therapeutic options that hold particular promise.

Original languageEnglish (US)
Pages (from-to)100-112
Number of pages13
JournalDiabetes Spectrum
Volume27
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Type 2 Diabetes Mellitus
Glucose
Insulin Resistance
Incretins
Lipolysis
Glucagon
Treatment Failure
Adipocytes
Neurotransmitter Agents
Disease Progression
Blood Glucose
Therapeutics
Insulin
Liver
Brain
Pharmaceutical Preparations
Renal Reabsorption

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Novel agents for the treatment of type 2 diabetes. / Defronzo, Ralph A; Triplitt, Curtis L; Abdul-ghani, Muhammad A; Cersosimo, Eugenio.

In: Diabetes Spectrum, Vol. 27, No. 2, 2014, p. 100-112.

Research output: Contribution to journalArticle

Defronzo, Ralph A ; Triplitt, Curtis L ; Abdul-ghani, Muhammad A ; Cersosimo, Eugenio. / Novel agents for the treatment of type 2 diabetes. In: Diabetes Spectrum. 2014 ; Vol. 27, No. 2. pp. 100-112.
@article{365712758a614d6ab61a8086e57c2efc,
title = "Novel agents for the treatment of type 2 diabetes",
abstract = "Impaired insulin secretion, increased hepatic glucose production, and decreased peripheral glucose utilization are the core defects responsible for the development and progression of type 2 diabetes. However, the pathophysiology of this disease also includes adipocyte insulin resistance (increased lipolysis), reduced incretin secretion/sensitivity, increased glucagon secretion, enhanced renal glucose reabsorption, and brain insulin resistance/neurotransmitter dysfunction. Although current diabetes management focuses on lowering blood glucose, the goal of therapy should be to delay disease progression and eventual treatment failure. Recent innovative treatment approaches target the multiple pathophysiological defects present in type 2 diabetes. Optimal management should include early initiation of combination therapy using multiple drugs with different mechanisms of action. This review examines novel therapeutic options that hold particular promise.",
author = "Defronzo, {Ralph A} and Triplitt, {Curtis L} and Abdul-ghani, {Muhammad A} and Eugenio Cersosimo",
year = "2014",
doi = "10.2337/diaspect.27.2.100",
language = "English (US)",
volume = "27",
pages = "100--112",
journal = "Diabetes Spectrum",
issn = "1040-9165",
publisher = "American Diabetes Association Inc.",
number = "2",

}

TY - JOUR

T1 - Novel agents for the treatment of type 2 diabetes

AU - Defronzo, Ralph A

AU - Triplitt, Curtis L

AU - Abdul-ghani, Muhammad A

AU - Cersosimo, Eugenio

PY - 2014

Y1 - 2014

N2 - Impaired insulin secretion, increased hepatic glucose production, and decreased peripheral glucose utilization are the core defects responsible for the development and progression of type 2 diabetes. However, the pathophysiology of this disease also includes adipocyte insulin resistance (increased lipolysis), reduced incretin secretion/sensitivity, increased glucagon secretion, enhanced renal glucose reabsorption, and brain insulin resistance/neurotransmitter dysfunction. Although current diabetes management focuses on lowering blood glucose, the goal of therapy should be to delay disease progression and eventual treatment failure. Recent innovative treatment approaches target the multiple pathophysiological defects present in type 2 diabetes. Optimal management should include early initiation of combination therapy using multiple drugs with different mechanisms of action. This review examines novel therapeutic options that hold particular promise.

AB - Impaired insulin secretion, increased hepatic glucose production, and decreased peripheral glucose utilization are the core defects responsible for the development and progression of type 2 diabetes. However, the pathophysiology of this disease also includes adipocyte insulin resistance (increased lipolysis), reduced incretin secretion/sensitivity, increased glucagon secretion, enhanced renal glucose reabsorption, and brain insulin resistance/neurotransmitter dysfunction. Although current diabetes management focuses on lowering blood glucose, the goal of therapy should be to delay disease progression and eventual treatment failure. Recent innovative treatment approaches target the multiple pathophysiological defects present in type 2 diabetes. Optimal management should include early initiation of combination therapy using multiple drugs with different mechanisms of action. This review examines novel therapeutic options that hold particular promise.

UR - http://www.scopus.com/inward/record.url?scp=84901951184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901951184&partnerID=8YFLogxK

U2 - 10.2337/diaspect.27.2.100

DO - 10.2337/diaspect.27.2.100

M3 - Article

VL - 27

SP - 100

EP - 112

JO - Diabetes Spectrum

JF - Diabetes Spectrum

SN - 1040-9165

IS - 2

ER -